Advanced Search

Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2014 December;26(4) > Minerva Biotecnologica 2014 December;26(4):223-33



A Journal on Biotechnology and Molecular Biology

Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246

Frequency: Quarterly

ISSN 1120-4826

Online ISSN 1827-160X


Minerva Biotecnologica 2014 December;26(4):223-33


Design of a chimeric DNA vaccine against Brucella spp.

Abkar M. 1, Lotfi A. S. 2, Amani J. 3, Ghorashi S. A. 4, Brujeni G. N. 5, Kamali M. 6

1 Department of Molecular Genetics, Faculty of Basic Sciences, Tarbiat Modares University, Tehran, Iran;
2 Department of Clinical Biochemistry, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran;
3 Applied Microbiology Research Center, Baqiyatallah Medical Science University, Tehran, Iran;
4 School of Animal and Veterinary Sciences, Charles Sturt University, Australia;
5 Department of Microbiology & Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran;
6 Nanobiotechnology Research Center, Baqiyatallah Medical Science University, Tehran, Iran

Brucellosis, a common illness between domestic animals and humans, is mostly caused by Brucella (B) abortus, B. melitensis and B.suis. It has been shown vaccination of mice by Omp19 and Omp31 can induce protection against different Brucella spp. Furthermore, urease enzyme is considered a virulence factor in most members of Brucella. Here, we designed a chimeric DNA vaccine containing omp19, omp31 and urease genes to obtain high protection against Brucella spp. The construct was analyzed using bioinformatics tools. Linear and discontinuous B-cell epitopes, MHC class I and II binding peptides of the chimeric vaccine were predicted. Results suggest the construct can be an appropriate vaccine candidate against brucellosis.

language: English


top of page